Current and Future Landscape of Cell and Gene Therapy – Analytics and Regulations

The cell and gene therapy market is poised for substantial expansion, with a projected global valuation of $42.56 billion by 2030, accompanied by a compound annual growth rate (CAGR) of 39.42% during the period 2022-2030. This growth has attracted a proliferation of emerging companies and promising technologies.

However, the nascent nature of the industry poses formidable challenges for regulators and quality professionals in ensuring the safety and efficacy of pioneering products. Sponsors are strongly advised to foster collaborations with Contract Development and Manufacturing Organizations (CDMOs) possessing expert quality teams to optimize project outcomes. Gain further insights into the pivotal contributions of quality teams and regulatory bodies to the advancement of cell and gene therapy by delving into the comprehensive discussion featuring Barry Conner, Vice President of Quality & Regulatory, and Michael Paeltz, M.D., Director of Quality Control at Matica Bio.

Download the whitepaper to learn more about analytics and regulations for cell and gene therapy products.

Get Your Copy